Journal of Headache and Pain

Article	Citations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019	473
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates	369
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update	200
Migraine and neuroinflammation: the inflammasome perspective	132
Comorbidities of primary headache disorders: a literature review with meta-analysis	97
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)	91
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs	79
Long COVID headache	78
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace	73
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials	73
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects	68
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine	68
Applying a biopsychosocial model to migraine: rationale and clinical implications	60
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months	59
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	54
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	53
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)	52
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis	50
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	44
Medication overuse and drug addiction: a narrative review from addiction perspective	43
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance	43
Association between response to triptans and response to erenumab: real-life data	42
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine	42
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis	41
Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020	40

Inflammatory complications of CGRP monoclonal antibodies: a case series	40
Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine	38
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients	38
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	38
Is there a causal relationship between stress and migraine? Current evidence and implications for management	37
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension	37
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	37
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	36
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes	36
Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study	36
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study	35
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine	35
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis	34
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention	34
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period	34
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure	33
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine	32
Immunogenicity of biologic therapies for migraine: a review of current evidence	30
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	30
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice	30
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury	29
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions	29
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i	27
Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities	27
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials	27
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid	26
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation	26
Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2	25
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience	25
Gray and white matter abnormalities in primary trigeminal neuralgia with and without neurovascular compression	24
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis	24
The Global Campaign turns 18: a brief review of its activities and achievements	24
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study	24
Brain barriers and their potential role in migraine pathophysiology	24
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients	24
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database	23
Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea	23
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension	23
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study	23
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine	22
Altered brain functional network dynamics in classic trigeminal neuralgia: a resting-state functional magnetic resonance imaging study	22
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	22
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch	22
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study	22
What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials	22
The role of deficient pain modulatory systems in the development of persistent post-traumatic headaches following mild traumatic brain injury: an exploratory longitudinal study	22
Whole-brain morphological alterations associated with trigeminal neuralgia	22
Demoralization predicts suicidality in patients with cluster headache	21
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	21
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures	21

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study	21
The patients’ perspective on the burden of idiopathic intracranial hypertension	21
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience	21
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology	20
21st century headache: mapping new territory	20
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience	20
A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine	20
Association between migraine and cognitive impairment	19
Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire	19
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials	19
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis	19
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	19
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-ana	19
A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan	19
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study	19
Assessment of normalized cerebral blood flow and its connectivity with migraines without aura during interictal periods by arterial spin labeling	19
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study	19
Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model	19
Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study	19
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany	19
FKN/CX3CR1 axis facilitates migraine-Like behaviour by activating thalamic-cortical network microglia in status epilepticus model rats	19
Cerebral perfusion variance in new daily persistent headache and chronic migraine: an arterial spin-labeled MR imaging study	19
Functional connectivity of the visual cortex differentiates anxiety comorbidity from episodic migraineurs without aura	18
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study	18
Burden of illness of trigeminal neuralgia among patients managed in a specialist center in England	18
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine	18
Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults	18
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)	18
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial	18
Exploring alterations in sensory pathways in migraine	17
Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress	17
The chronobiology of migraine: a systematic review	17
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	17
Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies	17
Mild traumatic brain injury is associated with effect of inflammation on structural changes of default mode network in those developing chronic pain	17
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials	17
Trends in utilization and costs of migraine medications, 2017–2020	16
Dynamic brainstem and somatosensory cortical excitability during migraine cycles	16
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms	16
Imaging the inflammatory phenotype in migraine	16
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study	16
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	16
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments	16
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine	16
Metabotropic glutamate receptor 5 regulates synaptic plasticity in a chronic migraine rat model through the PKC/NR2B signal	16
Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study	16
Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine	16
Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study	15
Flatness of the Meckel cave may cause primary trigeminal neuralgia: a radiomics-based study	15
Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series	15
The economic and personal burden of cluster headache: a controlled cross-sectional study	15
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study	15
Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model	15
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies	15
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury	15
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings	15
Post-reversible cerebral vasoconstriction syndrome headache	15
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	15
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	14
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials	14
P2X3 receptor upregulation in trigeminal ganglion neurons through TNFα production in macrophages contributes to trigeminal neuropathic pain in rats	14
Aberrant cerebral blood flow in tinnitus patients with migraine: a perfusion functional MRI study	14
Tracking the evolution of non-headache symptoms through the migraine attack	14
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies	14
A universal outcome measure for headache treatments, care-delivery systems and economic analysis	14
Functional connectivity and structural changes of thalamic subregions in episodic migraine	14
Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors	14
Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels	14
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study	14
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine	14
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms	14
Debate: Are cluster headache and migraine distinct headache disorders?	14
High concurrent validity between digital and analogue algometers to measure pressure pain thresholds in healthy participants and people with migraine: a cross-sectional study	13
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review	13
Thalamo-cortical networks in subtypes of migraine with aura patients	13
Altered static and dynamic functional network connectivity in post-traumatic headache	13
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	13
Src family kinases activity is required for transmitting purinergic P2X7 receptor signaling in cortical spreading depression and neuroinflammation	13
Phenome-wide analysis highlights putative causal relationships between self-reported migraine and other complex traits	13
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	13

Disconnectome of the migraine brain: a “connectopathy” model	13
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	13
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials	13
Early alterations of cortical thickness and gyrification in migraine without aura: a retrospective MRI study in pediatric patients	13
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study	13
Alterations in pain processing circuitries in episodic migraine	13
Mild traumatic brain injury affects the features of migraine	13
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	13
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	12
The bidirectional temporal relationship between headache and affective disorders: longitudinal data from the HUNT studies	12
Structural brain network characteristics in patients with episodic and chronic migraine	12
The relationship between headache-attributed disability and lost productivity: 1. A review of the literature	12
Clinical, psychological, and sensory characteristics associated with headache attributed to temporomandibular disorder in people with chronic myogenous temporomandibular disorder and primary headaches	12
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report	12
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study	12
Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study	12
Serum CGRP in migraine patients using erenumab as preventive treatment	12
Investigating the relationships between the burden of multiple sensory hypersensitivity symptoms and headache-related disability in patents with migraine	12
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials	12
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	12
Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time	12
Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults	12
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	12
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab	12
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup	12